These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. Burn DJ; Sawle GV; Brooks DJ J Neurol Neurosurg Psychiatry; 1994 Mar; 57(3):278-84. PubMed ID: 8158173 [TBL] [Abstract][Full Text] [Related]
8. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Brück A; Aalto S; Nurmi E; Vahlberg T; Bergman J; Rinne JO Mov Disord; 2006 Jul; 21(7):958-63. PubMed ID: 16550545 [TBL] [Abstract][Full Text] [Related]
9. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742 [TBL] [Abstract][Full Text] [Related]
10. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. Sawle GV; Playford ED; Burn DJ; Cunningham VJ; Brooks DJ Arch Neurol; 1994 Mar; 51(3):237-43. PubMed ID: 8129633 [TBL] [Abstract][Full Text] [Related]
11. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. Rakshi JS; Uema T; Ito K; Bailey DL; Morrish PK; Ashburner J; Dagher A; Jenkins IH; Friston KJ; Brooks DJ Brain; 1999 Sep; 122 ( Pt 9)():1637-50. PubMed ID: 10468504 [TBL] [Abstract][Full Text] [Related]
12. Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease. Dietz M; Harder S; Graff J; Künig G; Vontobel P; Leenders KL; Baas H Clin Pharmacol Ther; 2001 Jul; 70(1):33-41. PubMed ID: 11452242 [TBL] [Abstract][Full Text] [Related]
13. PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Yatham LN; Liddle PF; Shiah IS; Lam RW; Ngan E; Scarrow G; Imperial M; Stoessl J; Sossi V; Ruth TJ Am J Psychiatry; 2002 May; 159(5):768-74. PubMed ID: 11986130 [TBL] [Abstract][Full Text] [Related]
14. Modeling of fluorine-18-6-fluoro-L-Dopa in humans. Wahl L; Nahmias C J Nucl Med; 1996 Mar; 37(3):432-7. PubMed ID: 8772639 [TBL] [Abstract][Full Text] [Related]
15. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Guttman M; Léger G; Reches A; Evans A; Kuwabara H; Cedarbaum JM; Gjedde A Mov Disord; 1993 Jul; 8(3):298-304. PubMed ID: 8341294 [TBL] [Abstract][Full Text] [Related]
16. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brooks DJ; Salmon EP; Mathias CJ; Quinn N; Leenders KL; Bannister R; Marsden CD; Frackowiak RS Brain; 1990 Oct; 113 ( Pt 5)():1539-52. PubMed ID: 2123119 [TBL] [Abstract][Full Text] [Related]
17. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET. Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035 [TBL] [Abstract][Full Text] [Related]
18. Striatal kinetics of [11C]-(+)-nomifensine and 6-[18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography. Tedroff J; Aquilonius SM; Laihinen A; Rinne U; Hartvig P; Anderson J; Lundqvist H; Haaparanta M; Solin O; Antoni G Acta Neurol Scand; 1990 Jan; 81(1):24-30. PubMed ID: 2330812 [TBL] [Abstract][Full Text] [Related]